Status:
UNKNOWN
Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer
Lead Sponsor:
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Conditions:
Breast Cancer
Tumor Infiltrating Lymphocytes
Eligibility:
All Genders
18-90 years
Brief Summary
The morphological evaluation of Tumor-infiltrating Lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. In breast...
Detailed Description
This is a retrospective and prospective study in patients with Primary Breast cancer at Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI). This is a time-bound study, where we include a...
Eligibility Criteria
Inclusion
- Primary Breast cancer
- Completed scheduled treatment at SGPGI
- Adequate quality histopathology material available in Department of Pathology archives
- With minimum 6 months follow up
Exclusion
- Insufficient data
- Incomplete treatment
- Insufficient follow up information
- Insufficient histological material for review
Key Trial Info
Start Date :
January 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05250336
Start Date
January 19 2019
End Date
September 30 2022
Last Update
February 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Lucknow, Uttar Pradesh, India, 226014